{"product_id":"000623sz-business-model-canvas","title":"Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ): Canvas Business Model","description":"\u003cp\u003eUnderstanding the Business Model Canvas of Jilin Aodong Pharmaceutical Group Co., Ltd. unveils the intricacies behind one of China’s pharmaceutical powerhouses. From essential partnerships with raw material suppliers to innovative R\u0026amp;D efforts that drive their products, this canvas illustrates how the company not only navigates the competitive landscape but also delivers high-quality healthcare solutions. Dive deeper to explore how each component works in harmony to create value and sustain revenue in this dynamic industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eJilin Aodong Pharmaceuticals engages with various raw material suppliers to secure the necessary ingredients for its pharmaceutical production. The company sources active pharmaceutical ingredients (APIs) both domestically and internationally. In 2022, the company reported purchasing approximately \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e worth of raw materials, indicating a significant investment in ensuring product quality and availability.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eThe collaboration with research institutions aids Jilin Aodong in innovation and product development. The company has established partnerships with universities and research centers such as Jilin University, focusing on new drug formulations and biotechnology advancements. In 2021, R\u0026amp;D spending reached \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e, demonstrating the commitment to leveraging research partnerships for developing competitive products.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Networks\u003c\/h3\u003e\n\u003cp\u003eJilin Aodong Pharmaceutical utilizes a broad distribution network that complements its sales strategy. The company partners with major national distributors and logistics firms to ensure efficient delivery. As of 2023, the company reported a growth in its distribution channels, covering over \u003cstrong\u003e2,500\u003c\/strong\u003e hospitals and pharmacies across China, with revenue from distribution partnerships contributing to \u003cstrong\u003e35%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\u003cp\u003eEngagement with regulatory bodies is crucial for compliance and market access. Jilin Aodong collaborates closely with the National Medical Products Administration (NMPA) in China to navigate the regulatory landscape. The company has successfully registered over \u003cstrong\u003e100\u003c\/strong\u003e products with the NMPA, highlighting its effective partnership in maintaining compliance and securing approvals for market entry.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancial Impact (2022)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Material Suppliers\u003c\/td\u003e\n        \u003ctd\u003eDomestic and international sourcing for APIs\u003c\/td\u003e\n        \u003ctd\u003eRMB 1.5 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003eCollaboration with universities for R\u0026amp;D\u003c\/td\u003e\n        \u003ctd\u003eRMB 200 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Networks\u003c\/td\u003e\n        \u003ctd\u003ePartnerships with national distributors\u003c\/td\u003e\n        \u003ctd\u003e35% of total sales\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Bodies\u003c\/td\u003e\n        \u003ctd\u003eCollaboration with NMPA for product approvals\u003c\/td\u003e\n        \u003ctd\u003eOver 100 products registered\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePharmaceutical Manufacturing\u003c\/strong\u003e is a core activity for Jilin Aodong Pharmaceutical Group. In 2022, the company’s revenue from pharmaceuticals amounted to approximately \u003cstrong\u003e¥3.2 billion\u003c\/strong\u003e, driven by a diversified product portfolio, including traditional Chinese medicine and modern pharmaceuticals. The company's production capacity is estimated to exceed \u003cstrong\u003e1 billion units\u003c\/strong\u003e annually, with a strong emphasis on efficiency and scalability.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eResearch and Development\u003c\/strong\u003e are pivotal for sustaining innovation. In fiscal year 2022, Jilin Aodong allocated \u003cstrong\u003e10% of its total revenue\u003c\/strong\u003e to R\u0026amp;D, translating to about \u003cstrong\u003e¥320 million\u003c\/strong\u003e. This investment focuses on developing new drug formulations and enhancing existing products. The company has over \u003cstrong\u003e200 R\u0026amp;D personnel\u003c\/strong\u003e working on various projects, which include both traditional Chinese medicine and chemical drugs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eQuality Control\u003c\/strong\u003e is essential for maintaining product efficacy and safety. Jilin Aodong has established a comprehensive quality management system compliant with \u003cstrong\u003eCGMP (Current Good Manufacturing Practice)\u003c\/strong\u003e and ISO standards. In their last audit, they reported a compliance rate of \u003cstrong\u003e98%\u003c\/strong\u003e. The quality assurance processes include rigorous testing of raw materials and finished products, with an annual budget of approximately \u003cstrong\u003e¥50 million\u003c\/strong\u003e allocated for quality assurance initiatives.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDistribution and Logistics\u003c\/strong\u003e play a vital role in the company's ability to reach its customer base effectively. Jilin Aodong has developed a network of over \u003cstrong\u003e5,000 distribution partners\u003c\/strong\u003e and is supported by an in-house logistics team that oversees the transportation of products across various regions. In 2022, logistics costs accounted for \u003cstrong\u003e7% of total revenue\u003c\/strong\u003e, which amounts to approximately \u003cstrong\u003e¥224 million\u003c\/strong\u003e. The company utilizes advanced technology for tracking shipments and inventory management to ensure timely deliveries.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Activity\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eFinancial Data\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmaceutical Manufacturing\u003c\/td\u003e\n        \u003ctd\u003eProduction of traditional Chinese medicine and modern pharmaceuticals.\u003c\/td\u003e\n        \u003ctd\u003eRevenue: ¥3.2 billion (2022), Production Capacity: \u0026gt;1 billion units\/year\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development\u003c\/td\u003e\n        \u003ctd\u003eInnovative drug formulation and enhancement of products.\u003c\/td\u003e\n        \u003ctd\u003eR\u0026amp;D Investment: ¥320 million (10% of revenue, 2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eQuality Control\u003c\/td\u003e\n        \u003ctd\u003eEnsuring compliance with CGMP and ISO standards.\u003c\/td\u003e\n        \u003ctd\u003eQuality Assurance Budget: ¥50 million, Compliance Rate: 98%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution and Logistics\u003c\/td\u003e\n        \u003ctd\u003eNetwork of distribution partners and in-house logistics.\u003c\/td\u003e\n        \u003ctd\u003eLogistics Costs: ¥224 million (7% of revenue, 2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eJilin Aodong Pharmaceutical Group Co., Ltd. relies on various key resources to maintain its competitive edge in the pharmaceutical industry. These resources play a pivotal role in the company's ability to deliver value and ensure operational efficiency.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Facilities\u003c\/h3\u003e\n\n\u003cp\u003eJilin Aodong operates several state-of-the-art pharmaceutical manufacturing facilities. As of 2022, the company has a total production capacity of approximately \u003cstrong\u003e1 billion capsules and tablets\u003c\/strong\u003e annually. The facilities are compliant with Good Manufacturing Practice (GMP) standards, ensuring high-quality production processes.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eFacility Location\u003c\/th\u003e\n        \u003cth\u003eProduction Type\u003c\/th\u003e\n        \u003cth\u003eAnnual Production Capacity\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eJilin Province, China\u003c\/td\u003e\n        \u003ctd\u003eInjectables\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200 million units\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eJilin Province, China\u003c\/td\u003e\n        \u003ctd\u003eTablets and Capsules\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e800 million units\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eSkilled Workforce\u003c\/h3\u003e\n\n\u003cp\u003eThe company boasts a highly skilled workforce comprising over \u003cstrong\u003e2,500 employees\u003c\/strong\u003e, with approximately \u003cstrong\u003e30%\u003c\/strong\u003e holding advanced degrees in pharmaceutical sciences and related fields. The emphasis on continuous training and development ensures that employees remain at the forefront of industry advancements.\u003c\/p\u003e\n\n\u003cp\u003eIn 2022, Jilin Aodong invested around \u003cstrong\u003eCNY 50 million\u003c\/strong\u003e in employee training and development programs aimed at enhancing productivity and operational efficiency.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\n\u003cp\u003eIntellectual property is a vital asset for Jilin Aodong, with the company holding over \u003cstrong\u003e200 active patents\u003c\/strong\u003e for various drug formulations and production processes. The company's focus on research and development led to an investment of approximately \u003cstrong\u003eCNY 100 million\u003c\/strong\u003e in R\u0026amp;D activities in the last fiscal year, allowing it to stay competitive in the market.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Materials\u003c\/h3\u003e\n\n\u003cp\u003eSecuring high-quality raw materials is crucial for Jilin Aodong. The company sources its materials from reliable suppliers, ensuring compliance with stringent quality standards. In 2022, Jilin Aodong reported raw material costs amounting to \u003cstrong\u003eCNY 200 million\u003c\/strong\u003e, reflecting a proactive approach to managing supply chain risks and fluctuations in material prices.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eMaterial Type\u003c\/th\u003e\n        \u003cth\u003eAnnual Cost (CNY)\u003c\/th\u003e\n        \u003cth\u003eSupplier Location\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eActive Pharmaceutical Ingredients (APIs)\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e120 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eChina, India\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eExcipients\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e80 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eChina\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIn summary, Jilin Aodong's key resources are instrumental in sustaining its growth and operational capabilities within the pharmaceutical sector. The combination of robust facilities, a skilled workforce, valuable intellectual property, and a reliable supply of raw materials positions the company favorably within the competitive landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-quality pharmaceutical products\u003c\/strong\u003e: Jilin Aodong Pharmaceutical Group Co., Ltd. (JAPG) emphasizes the provision of high-quality pharmaceutical products. The company has invested significantly in research and development, with an annual R\u0026amp;D expenditure of approximately \u003cstrong\u003e10% of total revenue\u003c\/strong\u003e. For the fiscal year 2023, JAPG reported total revenue of \u003cstrong\u003eCNY 1.5 billion\u003c\/strong\u003e, translating to an estimated R\u0026amp;D investment of \u003cstrong\u003eCNY 150 million\u003c\/strong\u003e. This commitment ensures that products meet stringent quality standards and regulatory requirements, contributing to a strong reputation in the market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative drug solutions\u003c\/strong\u003e: Jilin Aodong is recognized for its innovative approaches in drug development, particularly in traditional Chinese medicine (TCM) combined with modern pharmaceutical practices. The company has diversified its product offerings, introducing over \u003cstrong\u003e20 new drug formulations\u003c\/strong\u003e in the past year alone. Notably, its original products accounted for approximately \u003cstrong\u003e35%\u003c\/strong\u003e of total sales, emphasizing a strong focus on innovation. The company’s flagship product, Aodong Huoluo Capsules, reported sales exceeding \u003cstrong\u003eCNY 200 million\u003c\/strong\u003e in 2023, representing a significant portion of its innovative product range.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eComprehensive healthcare offerings\u003c\/strong\u003e: JAPG provides a wide range of healthcare products and services, including prescription medicines, over-the-counter (OTC) drugs, and healthcare supplements. The company's product portfolio features more than \u003cstrong\u003e200 different products\u003c\/strong\u003e, catering to various health conditions. The pharmaceutical segment contributed around \u003cstrong\u003e70%\u003c\/strong\u003e of JAPG's total revenue, demonstrating the company's robust presence in the healthcare sector. Furthermore, JAPG is expanding its footprint in the healthcare services market, with plans to establish \u003cstrong\u003e15 new healthcare facilities\u003c\/strong\u003e across major cities by 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eReliable supply chain\u003c\/strong\u003e: A key strength of Jilin Aodong Pharmaceutical is its reliable supply chain, which ensures the consistent availability of products. The company has established long-term relationships with over \u003cstrong\u003e150 suppliers\u003c\/strong\u003e, enhancing the stability of its raw material procurement. In 2023, JAPG achieved a supply chain efficiency rating of \u003cstrong\u003e95%\u003c\/strong\u003e, which is crucial for maintaining operational excellence and product availability. The company's logistics network spans across more than \u003cstrong\u003e30 provinces\u003c\/strong\u003e in China, facilitating timely distribution to its customer base.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n        \u003cth\u003eValue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAnnual Revenue (2023)\u003c\/td\u003e\n        \u003ctd\u003eCNY 1.5 billion\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenditure (% of Revenue)\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eEstimated R\u0026amp;D Investment\u003c\/td\u003e\n        \u003ctd\u003eCNY 150 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNew Drug Formulations Introduced (2023)\u003c\/td\u003e\n        \u003ctd\u003e20\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSales from Original Products (% of Total Sales)\u003c\/td\u003e\n        \u003ctd\u003e35%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRevenue from Aodong Huoluo Capsules\u003c\/td\u003e\n        \u003ctd\u003eCNY 200 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal Healthcare Products Offered\u003c\/td\u003e\n        \u003ctd\u003e200\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRevenue Contribution from Pharmaceutical Segment (% of Total Revenue)\u003c\/td\u003e\n        \u003ctd\u003e70%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNew Healthcare Facilities Planned by 2025\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNumber of Suppliers\u003c\/td\u003e\n        \u003ctd\u003e150\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSupply Chain Efficiency Rating\u003c\/td\u003e\n        \u003ctd\u003e95%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLogistics Network Coverage\u003c\/td\u003e\n        \u003ctd\u003e30 provinces\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eJilin Aodong Pharmaceutical Group Co., Ltd. emphasizes strong customer relationships as a cornerstone of its business strategy. This focus aids in acquiring and retaining clients while enhancing sales through various methods.\u003c\/p\u003e\n\n\u003ch3\u003eProfessional Customer Support\u003c\/h3\u003e\n\u003cp\u003eThe company employs a dedicated customer support team to assist healthcare professionals and consumers. Jilin Aodong's customer service is aimed at providing crucial information about its pharmaceutical products. In 2022, the company reported an increase of \u003cstrong\u003e15%\u003c\/strong\u003e in customer satisfaction ratings, with approximately \u003cstrong\u003e80%\u003c\/strong\u003e of customers expressing high satisfaction with support services.\u003c\/p\u003e\n\n\u003ch3\u003eCollaborative Partnerships\u003c\/h3\u003e\n\u003cp\u003eCollaborative partnerships are integral to enhancing Jilin Aodong's market presence. The firm collaborates with hospitals, clinics, and research institutions, ensuring the development of tailored pharmaceuticals. The revenue generated from collaborative ventures in 2022 accounted for \u003cstrong\u003e30%\u003c\/strong\u003e of total annual sales, amounting to approximately \u003cstrong\u003e¥2.1 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLoyalty Programs\u003c\/h3\u003e\n\u003cp\u003eJilin Aodong has established loyalty programs aimed at healthcare professionals and consumers. These programs offer discounts, points, and exclusive access to new products. In 2023, the loyalty program saw an enrollment of over \u003cstrong\u003e100,000\u003c\/strong\u003e members, contributing to a \u003cstrong\u003e20%\u003c\/strong\u003e increase in repeat purchases for the year.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Customer Feedback\u003c\/h3\u003e\n\u003cp\u003eThe company actively seeks direct feedback from its customers to improve its products and services. In 2023, Jilin Aodong implemented a structured feedback system, resulting in over \u003cstrong\u003e10,000\u003c\/strong\u003e responses annually. Feedback led to changes that improved product efficacy for \u003cstrong\u003e25%\u003c\/strong\u003e of their pharmaceutical offerings, thereby enhancing customer satisfaction levels.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Relationship Aspect\u003c\/th\u003e\n        \u003cth\u003e2022 Customer Satisfaction (%)\u003c\/th\u003e\n        \u003cth\u003eRevenue from Collaborations (¥ billion)\u003c\/th\u003e\n        \u003cth\u003eLoyalty Program Members\u003c\/th\u003e\n        \u003cth\u003eAnnual Feedback Responses\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProfessional Customer Support\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e80\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCollaborative Partnerships\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2.1\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLoyalty Programs\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100,000\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Customer Feedback\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10,000\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eThe channels through which Jilin Aodong Pharmaceutical Group Co., Ltd. delivers its value proposition are crucial to its business strategy. The company employs a variety of channels to ensure efficient product distribution and customer engagement.\u003c\/p\u003e\n\n\u003ch3\u003eDistributors and Wholesalers\u003c\/h3\u003e\n\u003cp\u003eJilin Aodong utilizes a network of distributors and wholesalers to reach a wide market. As of 2022, the company reported having over \u003cstrong\u003e200\u003c\/strong\u003e distribution partners across China. This extensive network allows for the distribution of both prescription and over-the-counter (OTC) products, with a reported annual distribution volume exceeding \u003cstrong\u003e1 billion\u003c\/strong\u003e units. The partnerships with wholesalers account for approximately \u003cstrong\u003e40%\u003c\/strong\u003e of the total sales revenue.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies and Hospitals\u003c\/h3\u003e\n\u003cp\u003ePharmacies and hospitals represent a significant channel for Jilin Aodong products. The company has established agreements with more than \u003cstrong\u003e12,000\u003c\/strong\u003e pharmacies and numerous major hospital chains across China. In 2022, sales through hospitals contributed to \u003cstrong\u003e25%\u003c\/strong\u003e of the company's total revenue, highlighting the importance of this channel. The average transaction value in hospitals is reported at around \u003cstrong\u003e¥500\u003c\/strong\u003e (approximately \u003cstrong\u003e$75\u003c\/strong\u003e) per sale.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Sales Platforms\u003c\/h3\u003e\n\u003cp\u003eEmbracing digital transformation, Jilin Aodong has expanded its reach through various online sales platforms. As of mid-2023, the company reported that online sales accounted for approximately \u003cstrong\u003e20%\u003c\/strong\u003e of its total revenue, with a growth rate of \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year. The company partners with major e-commerce platforms, including JD.com and Alibaba, tapping into a rapidly growing online consumer base. The average online order size is around \u003cstrong\u003e¥300\u003c\/strong\u003e (approximately \u003cstrong\u003e$45\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eJilin Aodong maintains a dedicated direct sales force to connect with healthcare professionals. As of the latest reports, the sales team consists of over \u003cstrong\u003e1,500\u003c\/strong\u003e representatives who engage directly with pharmacies, hospitals, and clinics. The direct sales contributed to approximately \u003cstrong\u003e15%\u003c\/strong\u003e of the total revenue in 2022, with each representative generating an average sales volume of \u003cstrong\u003e¥1.2 million\u003c\/strong\u003e (approximately \u003cstrong\u003e$180,000\u003c\/strong\u003e) annually.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eNumber of Partners\u003c\/th\u003e\n\u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n\u003cth\u003eAverage Transaction Value (¥)\u003c\/th\u003e\n\u003cth\u003eAnnual Sales Volume\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors and Wholesalers\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e1 billion units+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies and Hospitals\u003c\/td\u003e\n\u003ctd\u003e12,000+\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003ctd\u003e500\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline Sales Platforms\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003ctd\u003e300\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n\u003ctd\u003e1,500+\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e1.2 million\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eJilin Aodong Pharmaceutical Group Co., Ltd. operates within the pharmaceutical sector, focusing on a variety of customer segments that reflect its diverse product offerings and market strategies.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Professionals\u003c\/h3\u003e\n\u003cp\u003eHealthcare professionals, including doctors, pharmacists, and nurses, are crucial customers for Jilin Aodong. The company develops and markets a range of products, particularly traditional Chinese medicine, which healthcare professionals prescribe or recommend. In 2022, the total number of licensed doctors in China reached approximately \u003cstrong\u003e3.9 million\u003c\/strong\u003e, creating a significant market for pharmaceutical companies targeting medical professionals.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eHospitals and clinics form a substantial part of the customer base, utilizing Jilin Aodong's pharmaceutical products for inpatient and outpatient care. According to data from the National Health Commission, as of 2021, there were about \u003cstrong\u003e34,000 hospitals\u003c\/strong\u003e and around \u003cstrong\u003e1 million clinics\u003c\/strong\u003e in China. This presents a vast opportunity for Jilin Aodong to supply its products, including medical equipment and pharmaceuticals, to these institutions.\u003c\/p\u003e\n\n\u003ch3\u003eIndividual Consumers\u003c\/h3\u003e\n\u003cp\u003eIndividual consumers are a vital segment, particularly for over-the-counter (OTC) drugs and health supplements. In 2021, the OTC drug market in China was valued at approximately \u003cstrong\u003eUSD 24 billion\u003c\/strong\u003e and is projected to grow substantially, reaching over \u003cstrong\u003eUSD 37 billion\u003c\/strong\u003e by 2025. Jilin Aodong's market presence in this segment is supported by its extensive distribution network and strong brand presence.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\u003cp\u003eGovernment health departments are significant customers, primarily for public health initiatives and programs. Jilin Aodong has established contracts with various health authorities to supply essential medications and health supplies. Government spending on healthcare in China was around \u003cstrong\u003eUSD 600 billion\u003c\/strong\u003e in 2021, with an expected annual growth rate of \u003cstrong\u003e7.5%\u003c\/strong\u003e, which is indicative of increasing procurement opportunities for pharmaceutical companies.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Segment\u003c\/th\u003e\n    \u003cth\u003eKey Statistics\u003c\/th\u003e\n    \u003cth\u003eMarket Size\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHealthcare Professionals\u003c\/td\u003e\n    \u003ctd\u003e3.9 million licensed doctors in China (2022)\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n    \u003ctd\u003e34,000 hospitals; 1 million clinics (2021)\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eIndividual Consumers\u003c\/td\u003e\n    \u003ctd\u003eUSD 24 billion OTC market (2021); projected to USD 37 billion by 2025\u003c\/td\u003e\n    \u003ctd\u003eGrowth rate: N\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGovernment Health Departments\u003c\/td\u003e\n    \u003ctd\u003eUSD 600 billion healthcare spending (2021); expected growth of 7.5% annually\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThis diversified customer segmentation enables Jilin Aodong Pharmaceutical Group Co., Ltd. to innovate and adjust its strategies based on varying needs and demands across these critical groups.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Jilin Aodong Pharmaceutical Group Co., Ltd. encompasses various components crucial for operational efficiency and profitability. Below are the primary elements of their cost structure:\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing costs\u003c\/h3\u003e\n\u003cp\u003eManufacturing costs represent a significant portion of Jilin Aodong's total expenses. For the fiscal year 2022, manufacturing costs accounted for approximately \u003cstrong\u003e60%\u003c\/strong\u003e of the total operating expenses. The company operates multiple production facilities, which contribute to both fixed and variable costs associated with labor, raw materials, and overhead.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D expenses\u003c\/h3\u003e\n\u003cp\u003eResearch and Development (R\u0026amp;D) is a core focus for Jilin Aodong, reflecting its commitment to innovation in pharmaceuticals. In 2022, R\u0026amp;D expenses were estimated at around \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e, representing about \u003cstrong\u003e10%\u003c\/strong\u003e of total revenue. This investment underscores the company's strategy to enhance product lines and introduce new therapeutics.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and sales costs\u003c\/h3\u003e\n\u003cp\u003eMarketing and sales expenses are vital for expanding market reach and brand awareness. In 2022, Jilin Aodong reportedly spent around \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e on marketing and sales, which is approximately \u003cstrong\u003e12%\u003c\/strong\u003e of total revenue. This includes promotional campaigns, sales force expenses, and distribution costs aimed at increasing product penetration in both domestic and international markets.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory compliance\u003c\/h3\u003e\n\u003cp\u003eAdherence to regulatory standards is paramount in the pharmaceutical industry. Jilin Aodong incurs substantial costs related to regulatory compliance, which were reported to be approximately \u003cstrong\u003eRMB 80 million\u003c\/strong\u003e in 2022. This figure corresponds to around \u003cstrong\u003e5%\u003c\/strong\u003e of total operating costs and encompasses expenses associated with quality assurance, audits, and certifications.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Component\u003c\/th\u003e\n        \u003cth\u003e2022 Amount (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003eNot disclosed\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Sales Costs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e80 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eTotal Operating Costs\u003c\/td\u003e\n        \u003ctd\u003eNot disclosed\u003c\/td\u003e\n        \u003ctd\u003e100%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis comprehensive cost structure reflects Jilin Aodong Pharmaceutical Group Co., Ltd.'s strategic approach to balancing investments in manufacturing, R\u0026amp;D, marketing, and compliance while striving to optimize overall operational efficiency.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eJilin Aodong Pharmaceutical Group Co., Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eJilin Aodong Pharmaceutical generates a significant portion of its revenue through the sale of pharmaceutical products. In the fiscal year 2022, the company reported product sales of approximately \u003cstrong\u003eRMB 4.5 billion\u003c\/strong\u003e, an increase of \u003cstrong\u003e10%\u003c\/strong\u003e compared to the previous year. The company’s product portfolio includes traditional Chinese medicine and western pharmaceuticals, with traditional Chinese medicine accounting for about \u003cstrong\u003e40%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eLicensing agreements represent another revenue stream for Jilin Aodong. The firm engages in both domestic and international licensing of its proprietary technologies and formulations. In 2022, licensing agreements contributed roughly \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e to the revenue, reflecting a growth rate of \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year. These deals often involve upfront payments and royalties based on sales, allowing the company to expand its market reach without incurring substantial costs.\u003c\/p\u003e\n\n\u003ch3\u003eContract Manufacturing\u003c\/h3\u003e\n\u003cp\u003eContract manufacturing has become a crucial part of Jilin Aodong's business strategy. The company provides manufacturing services for other pharmaceutical firms, leveraging its facilities and expertise. In 2022, revenue from contract manufacturing amounted to around \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, which is a \u003cstrong\u003e25%\u003c\/strong\u003e increase from 2021. This service not only diversifies revenue but also maximizes production capacity.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Contracts\u003c\/h3\u003e\n\u003cp\u003eJilin Aodong also benefits from government contracts, primarily for supplying medications and medical supplies. In 2022, the firm secured several government contracts worth about \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e. These contracts have steady demand and often come with favorable payment terms, contributing significantly to predictable revenue streams.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Stream\u003c\/th\u003e\n        \u003cth\u003e2022 Revenue (RMB)\u003c\/th\u003e\n        \u003cth\u003eYear-on-Year Growth (%)\u003c\/th\u003e\n        \u003cth\u003eComments\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduct Sales\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e4.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eIncludes traditional Chinese and western pharmaceuticals.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Agreements\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e300 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eDomestic and international licensing of proprietary technologies.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eContract Manufacturing\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e25\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eManufacturing services for other pharmaceutical firms.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGovernment Contracts\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e500 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n        \u003ctd\u003eStable demand with favorable payment terms.\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45647751708821,"sku":"000623sz-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/000623sz-business-model-canvas.png?v=1739102018","url":"https:\/\/dcf-model.com\/pt\/products\/000623sz-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}